Literature DB >> 12499179

Ribavirin quantification in combination treatment of chronic hepatitis C.

Sylvie Larrat1, Françoise Stanke-Labesque, Agnès Plages, Jean-Pierre Zarski, Germain Bessard, Claude Souvignet.   

Abstract

Ribavirin in combination with alpha 2 interferon is the consensus treatment for chronic hepatitis C. However, recent preliminary pharmacological studies have suggested that the bioavailability of ribavirin displays great interindividual variability. In order to monitor serum ribavirin levels during combination treatment, we developed and validated a quantitative assay using an approach adaptable for routine hospital laboratories. The method involved solid-phase extraction on phenyl boronic acid cartridges followed by high-performance liquid chromatography with a C(18)-bonded silica column and a mobile phase containing 10 mM ammonium phosphate buffer (with the pH adjusted to 2.5) and UV detection (207 nm). The sensitivity, recovery, linearity of the calibration curve, intra- and interassay accuracies, precision, and stability at 4 degrees C were consistent with its use in the laboratory routine. In addition, other nucleoside analogues sometimes used with ribavirin in patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus did not interfere with the quantification of ribavirin levels. The ribavirin concentration was quantified in 24 serum samples from patients with chronic hepatitis C treated with a combination of ribavirin and alpha 2 interferon. The mean serum ribavirin concentration was 2.67 +/- 1.06 micro g/ml (n = 24) at week 12 of treatment (W12) and 3.24 +/- 1.35 micro g/ml (n = 24) at week 24 of treatment (W24). In addition, ribavirin concentrations displayed high interindividual variabilities: the coefficients of variation of the serum ribavirin concentrations adjusted to the administered dose were 44 and 48% at W12 and W24, respectively. Moreover, the ribavirin concentration was higher in patients with a sustained virological response (n = 11) than in patients with treatment failure (n = 13), with significant intergroup differences at W12 (P = 0.030) and W24 (P = 0.049). The present study describes a simple analytical method for the quantification of ribavirin in human serum that could be a useful tool for the monitoring of ribavirin concentrations in HCV-infected patients in order to improve the efficacy and safety of therapy with ribavirin plus interferon.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12499179      PMCID: PMC149002          DOI: 10.1128/AAC.47.1.124-129.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Determination of ribavirin in serum using highly selective solid-phase extraction and high-performance liquid chromatography.

Authors:  J O Svensson; A Bruchfeld; R Schvarcz; L Ståhle
Journal:  Ther Drug Monit       Date:  2000-04       Impact factor: 3.681

2.  Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study.

Authors:  J H Braconier; O Paulsen; K Engman; A Widell
Journal:  Scand J Infect Dis       Date:  1995

3.  Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report.

Authors:  V P Shah; K K Midha; S Dighe; I J McGilveray; J P Skelly; A Yacobi; T Layloff; C T Viswanathan; C E Cook; R D McDowall
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Oct-Dec       Impact factor: 2.441

4.  High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes.

Authors:  M Homma; A L Jayewardene; J Gambertoglio; F Aweeka
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

5.  Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.

Authors:  S L Preston; G L Drusano; P Glue; J Nash; S K Gupta; P McNamara
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 6.  The clinical pharmacology of ribavirin.

Authors:  P Glue
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

Review 7.  Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C.

Authors:  G L Davis
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

8.  Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C.

Authors:  J G McHutchison; T Poynard
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

Review 9.  Antiviral therapy for patients with chronic hepatitis C.

Authors:  J Heathcote
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

10.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

View more
  22 in total

1.  Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication.

Authors:  Victor E Buckwold; Jiayi Wei; Michelle Wenzel-Mathers; Julie Russell
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

Review 2.  The application and mechanism of action of ribavirin in therapy of hepatitis C.

Authors:  Emmanuel Thomas; Marc G Ghany; T Jake Liang
Journal:  Antivir Chem Chemother       Date:  2012-09-25

3.  Pharmacokinetics of ribavirin in patients with hepatitis C virus.

Authors:  Janet R Wade; Eric Snoeck; Frank Duff; Matthew Lamb; Karin Jorga
Journal:  Br J Clin Pharmacol       Date:  2006-12       Impact factor: 4.335

4.  Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.

Authors:  Eric Snoeck; Janet R Wade; Frank Duff; Matthew Lamb; Karin Jorga
Journal:  Br J Clin Pharmacol       Date:  2006-12       Impact factor: 4.335

5.  Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections.

Authors:  Hidetsugu Saito; Shinichiro Tada; Hirotoshi Ebinuma; Hiromasa Ishii; Kazuo Kashiwazaki; Masahiko Takahashi; Nobuhiro Tsukada; Jiro Nishida; Shin Tanaka; Hiroshi Shiozaki; Toshifumi Hibi
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

6.  Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.

Authors:  Andrew H Talal; Ruei-Chi Liu; Marija Zeremski; Rositsa Dimova; Lorna Dove; Daniel Pearce; Tarek Hassanein; Leleka Doonquah; David Aboulafia; Jorge Rodriguez; Hector Bonilla; Jeffrey Galpin; Judy A Aberg; Barbara Johnston; Marshall J Glesby; Ira M Jacobson
Journal:  J Acquir Immune Defic Syndr       Date:  2011-11-01       Impact factor: 3.731

7.  Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1.

Authors:  Runyan Jin; Ling Cai; Ming Tan; John G McHutchison; Thomas C Dowling; Charles D Howell
Journal:  Am J Gastroenterol       Date:  2012-10-23       Impact factor: 10.864

8.  Convenient biological assay for polyethylene glycol-interferons in patients with hepatitis C.

Authors:  Anne Boulestin; Nassim Kamar; Florence Legrand-Abravanel; Karine Sandres-Saune; Laurent Alric; Jean-Pierre Vinel; Lionel Rostaing; Jacques Izopet
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity.

Authors:  Julie K Pfeiffer; Karla Kirkegaard
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-16       Impact factor: 11.205

10.  Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon.

Authors:  Yannick Debing; Suzanne U Emerson; Yijin Wang; Qiuwei Pan; Jan Balzarini; Kai Dallmeier; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.